<DOC>
	<DOCNO>NCT00111306</DOCNO>
	<brief_summary>The purpose study evaluate safety &amp; efficacy Epratuzumab standard treatment patient SLE .</brief_summary>
	<brief_title>Study Epratuzumab Systemic Lupus Erythematosus</brief_title>
	<detailed_description />
	<mesh_term>Lupus Erythematosus , Systemic</mesh_term>
	<criteria>Has SLE ACR revise criterion ( meet &lt; 4 criterion ) ; Has SLE least one elevate lupus antibody ; Has new onset severe lupus disease flare least one body organ system , exclude renal neurologic Active severe CNS Renal disease define BILAG Level A Allergy murine human antibody Antiphospholid antibody AND history thrombocytopenic event</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Lupus</keyword>
	<keyword>Antibody</keyword>
	<keyword>B-cell immunotherapy</keyword>
</DOC>